Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Adam on +441494 818 010 or adam@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Adam Woolley
Recruitment Consultant
adam@zenopa.com
+441494 818 010

Testimonials
It has been an absolute pleasure dealing with Zenopa ever since I registered an interest in finding a new employment opportunity.
Bobby, 2012

Ferring's Firmagon shows long-term efficacy in study

1 September 2011 00:00 in Pharmaceutical Company Product News


Ferring has highlighted data from a new clinical study that supports the long-term efficacy of Firmagon, its approved treatment for prostate cancer.

Results from a study published in the Journal of Urology show that the gonadotropin-releasing hormone therapy continued to be effective and well-tolerated among patients after a three-year period.

Data was gleaned from an extension to a one-year phase III trial - which previously demonstrated Firmagon's benefits compared to leuprolide - with the three-year findings showing that its progression-free survival performance can be sustained.

Firmagon is already ratified for sale as an advanced prostate cancer therapy in both the EU and US.

Dr E David Crawford, head of urologic oncology at the University of Colorado Denver, said: "Being able to delay castration resistance for as long as possible is an important outcome for any first-line therapy."

Last month, InPharm reported that Ferring has relocated to a new UK base at Drayton Hall near London, which will help to support its continued growth in the region.ADNFCR-8000103-ID-800716060-ADNFCR

Other news stories from 01/09/2011

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd